<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622749</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001227</org_study_id>
    <secondary_id>1T32NS100663-01</secondary_id>
    <nct_id>NCT03622749</nct_id>
  </id_info>
  <brief_title>Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders</brief_title>
  <official_title>Pilot Study of Neuromodulation for Enhancement of Emotion Regulation in Bipolar Mood Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are conducting this research study to better understand how individuals&#xD;
      with bipolar disorder regulate their emotions, and if the study can use a technique called&#xD;
      &quot;transcranial magnetic stimulation&quot; or TMS to help improve emotion regulation for individuals&#xD;
      with bipolar disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emotion dysregulation contributes to the development and maintenance of a wide range of&#xD;
      psychopathology, but is especially relevant for individuals with bipolar mood disorders (BD).&#xD;
      These individuals experience severe and episodic emotion dysregulation associated with&#xD;
      maladaptive functioning, interpersonal problems, decreased work productivity, and suicidal&#xD;
      ideation and behavior. To date, both pharmacological and psychosocial treatments fail to&#xD;
      normalize emotion dysregulation for many bipolar patients. As a consequence, all too many&#xD;
      experience poor outcomes. Thus, there is a significant need for new innovative approaches to&#xD;
      target and improve emotion dysregulation in bipolar patients. Non-invasive neuromodulation&#xD;
      using transcranial magnetic stimulation (TMS) may provide a viable strategy to help improve&#xD;
      emotion dysregulation in bipolar mood disorders. As a first step to test this hypothesis, the&#xD;
      current proposal seeks to experimentally identify specific neural target sites for improving&#xD;
      emotion regulation using TMS. If the investigators can demonstrate target engagement of&#xD;
      emotion regulation at the behavioral level using TMS, this will provide an important first&#xD;
      step towards examining the potential utility of TMS as a viable strategy to help improve&#xD;
      emotion dysregulation in bipolar mood disorders. While this is not a definitive clinical&#xD;
      trial, the sham-controlled double-crossover design of this study will provide valuable&#xD;
      information for target site selection for the development of TMS as an intervention strategy&#xD;
      to improve emotion dysregulation in BD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Emotion Conflict Resolution Task</measure>
    <time_frame>Change from baseline to 15 minutes post-TMS stimulation</time_frame>
    <description>Slope of reaction time (milliseconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Cognitive Reappraisal Task</measure>
    <time_frame>Change from baseline to 15 minutes post-TMS stimulation</time_frame>
    <description>Distress rating (scale 1- 4)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Transcranial Magnetic Stimulation</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with Bipolar 1 Disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Non-Invasive neuromodulation</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  Men and women&#xD;
&#xD;
               -  Ages 18-50 years&#xD;
&#xD;
               -  Patients diagnosed with bipolar I disorder (BD-I), current mood state euthymic.&#xD;
&#xD;
               -  On a stable psychiatric medication regimen for at least a month prior to and&#xD;
                  during study participation&#xD;
&#xD;
        Healthy Controls:&#xD;
&#xD;
          -  Men and women&#xD;
&#xD;
          -  Ages 18-50 years&#xD;
&#xD;
          -  Without major psychiatric illness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients&#xD;
&#xD;
               -  Any change in psychiatric medications within a month prior to and during study&#xD;
                  participation&#xD;
&#xD;
               -  Legal or mental incompetency&#xD;
&#xD;
               -  Intellectual disability&#xD;
&#xD;
               -  Current manic (YMRS &gt; 12) or severe depressive episode (HAM-D-17 &gt; 5)&#xD;
&#xD;
               -  Substance use disorder (abuse or dependence) with active use within the last 3&#xD;
                  months&#xD;
&#xD;
               -  Significant medical or neurological illness&#xD;
&#xD;
               -  Prior neurosurgical procedure&#xD;
&#xD;
               -  History of seizures&#xD;
&#xD;
               -  History of ECT treatment or clinical TMS within the past three months&#xD;
&#xD;
               -  Implanted cardiac pacemakers&#xD;
&#xD;
               -  Patients who have conductive, ferromagnetic or other magnetic-sensitive metals&#xD;
                  implanted in their head or neck, or are non-removable and within 30 cm of the&#xD;
                  treatment coil. These include:&#xD;
&#xD;
                    -  Aneurysm clips or coils&#xD;
&#xD;
                    -  Carotid or cerebral stents&#xD;
&#xD;
                    -  Metallic devices implanted in the head (e.g. Implanted pacemaker, medication&#xD;
                       pump, vagal stimulator, deep brain stimulator, TENS unit, or&#xD;
                       ventriculo-peritoneal shunt)&#xD;
&#xD;
                    -  Magnetically active dental implants&#xD;
&#xD;
                    -  Cochlear/otologic implants&#xD;
&#xD;
                    -  CSF shunts&#xD;
&#xD;
                    -  Ferromagnetic ocular implants&#xD;
&#xD;
                    -  Pellets, bullets, fragments less than 30 cm from the coil&#xD;
&#xD;
                    -  Facial tattoos with metallic ink, permanent makeup less than 30 cm from the&#xD;
                       coil&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
        Healthy Controls:&#xD;
&#xD;
          -  History of major psychiatric illness, including psychosis&#xD;
&#xD;
          -  Has a first-degree relative with psychosis&#xD;
&#xD;
          -  Active use of neuropsychoactive medications&#xD;
&#xD;
          -  Legal or mental incompetency&#xD;
&#xD;
          -  Intellectual disability&#xD;
&#xD;
          -  Substance use disorder (abuse or dependence) with active use within the last 3 months&#xD;
&#xD;
          -  Significant medical or neurological illness&#xD;
&#xD;
          -  Prior neurosurgical procedure&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  History of ECT treatment or clinical TMS within the past three months&#xD;
&#xD;
          -  Implanted cardiac pacemakers&#xD;
&#xD;
          -  Individuals who have conductive, ferromagnetic or other magnetic-sensitive metals&#xD;
             implanted in their head or neck, or are non-removable and within 30 cm of the&#xD;
             treatment coil. These include:&#xD;
&#xD;
               -  Aneurysm clips or coils&#xD;
&#xD;
               -  Carotid or cerebral stents&#xD;
&#xD;
               -  Metallic devices implanted in the head (e.g. Implanted pacemaker, medication&#xD;
                  pump, vagal stimulator, deep brain stimulator, TENS unit, or&#xD;
                  ventriculo-peritoneal shunt)&#xD;
&#xD;
               -  Magnetically active dental implants&#xD;
&#xD;
               -  Cochlear/otologic implants&#xD;
&#xD;
               -  CSF shunts&#xD;
&#xD;
               -  Ferromagnetic ocular implants&#xD;
&#xD;
               -  Pellets, bullets, fragments less than 30 cm from the coil&#xD;
&#xD;
               -  Facial tattoos with metallic ink, permanent makeup less than 30 cm from the coil&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen K Ellard, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis Worthley, BA</last_name>
    <phone>617-724-8780</phone>
    <email>er-studies@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Blake Andreou, BA</last_name>
    <phone>617-724-8780</phone>
    <email>er-studies@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Martinos Center for Biomedical Imaging</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen K Ellard, PhD</last_name>
      <phone>617-724-3221</phone>
      <email>kellard@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen K Ellard, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Kristen K. Ellard, Ph.D.</investigator_full_name>
    <investigator_title>Instructor in Psychology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

